Clinical Trial Update: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intravenous Wharton's Jelly-derived mesenchymal stem cells for acute respiratory distress syndrome due to COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Wharton's Jelly Derived Mesenchymal Stem Cells (mesenchymal stem cells)

Snippet

Sponsor: BioXcellerator | Conditions: Acute Respiratory Distress Syndrome | Phase 1, Phase 2 | Status: TERMINATED